Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 09 - 07 save search
Global Cancer Diagnostics Market to Reach $213.7 Billion by 2026
Published: 2021-09-07 (Crawled : 16:00) - prnewswire.com
PFE | News 4 | $26.185 -0.51% 6.6M
|
Health Technology
|
| O: 0.23%
H: 1.09%
C: -0.51%
GSK | News | $40.755 -1.18% 660K
|
Health Technology
|
| O: -0.84%
H: 0.1%
C: -0.78%
LLY | News | $731.81 -1.86% 1M
|
Health Technology
|
| O: -0.41%
H: 0.7%
C: -1.62%
CTS | News | $45.185 -0.67% 19K
|
Electronic Technology
|
| O: -0.09%
H: 0.09%
C: -1.28%
BDX | $234.225 -0.06% 330K
|
Health Technology
|
| O: 0.0%
H: 0.39%
C: 0.0%
A | $136.7 -1.8% 470K
|
Health Technology
|
| O: 1.12%
H: 0.05%
C: -0.87%
ABT | News | $106.78 -0.75% 2M
|
Health Technology
|
| O: -0.53%
H: 0.28%
C: 0.21%
ILMN | $121.3 -2.54% 310K
|
Health Technology
|
| O: -0.27%
H: 0.03%
C: -0.87%
HOLX | $76.98 -0.27% 210K
|
Health Technology
|
| O: -0.54%
H: 0.29%
C: -0.04%
AZN | News | $71.065 0.3% 3.2M
|
Health Technology
|
| O: 0.31%
H: 0.02%
C: -1.05%
cancer diagnostics diagnostic
New Analysis from Global Industry Analysts Reveals Steady Growth for Cancer/Tumor Profiling, with the Market to Reach $10.7 Billion Worldwide by 2026
Published: 2021-09-07 (Crawled : 14:15) - prnewswire.com
NSTG M | $0.1053 -37.43% -0.19% 0
|
Health Technology
|
| O: -0.71%
H: 1.13%
C: -1.99%
ILMN | $121.3 -2.54% 310K
|
Health Technology
|
| O: -0.27%
H: 0.03%
C: -0.87%
HTGM | $0.48 -20.0% -26.08% 0
|
Health Technology
|
| O: 0.78%
H: 0.92%
C: -1.85%
cancer growth
Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
CADL | $5.85 -1.02% 470K
|
|
| O: 1.84%
H: 28.19%
C: 20.0%
media treatment risk prostate cancer cancer phase 3 trial enroll
Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
Published: 2021-09-07 (Crawled : 14:00) - biospace.com/
MYGN | $18.525 -0.4% 99K
|
Health Technology
|
| O: 0.56%
H: 0.58%
C: -2.43%
ILMN | $121.3 -2.54% 310K
|
Health Technology
|
| O: -0.27%
H: 0.03%
C: -0.87%
test cancer research commercialization diagnostic
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications
Published: 2021-09-07 (Crawled : 12:15) - biospace.com/
RDY | $71.31 -0.25% 25K
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: -0.48%
CTXR | $0.7338 -4.37% 390K
|
Health Technology
|
| O: 3.37%
H: 5.93%
C: -1.4%
treatment immunotherapy therapy cancer license phase 3 t-cell e7777
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360® Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer
Published: 2021-09-07 (Crawled : 12:15) - globenewswire.com
GH | News 4 | $17.69 2.02% 520K
|
Health Services
|
| O: -0.01%
H: 1.86%
C: 1.07%
blood lung cancer test genomic cancer conference
Natera's Signatera® Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Guided Treatment in Stage II-III Colon Cancer
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
NTRA | News M | $92.61 1.73% 140K
|
Health Services
|
| O: 1.99%
H: 1.12%
C: -0.91%
treatment test cancer
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
Published: 2021-09-07 (Crawled : 12:00) - biospace.com/
ADAP | $1.08 -5.26% 330K
|
Health Technology
|
| O: 23.48%
H: 11.8%
C: 4.43%
collaboration cancer research t-cell commercialization therapy
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Published: 2021-09-07 (Crawled : 07:00) - globenewswire.com
TLSA | News | $0.751 -3.1% 190K
|
Health Technology
|
| O: 4.69%
H: 1.99%
C: -1.0%
treatment foralumab cancer antibody license car-t
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.05 44.75% 13M
|
Technology Services
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.